Cargando…

Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis

Tyrosine kinases (TK) are enzymes capable of transferring phosphate groups to tyrosine residues in cytoplasmic proteins or the intracellular domains of transmembrane receptors. TK play critical roles in diverse biological functions including cellular processes such as adhesion, motility, proliferati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomez-Puerta, Jose A., Mócsai, Attila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3796894/ https://www.ncbi.nlm.nih.gov/pubmed/23574525 http://dx.doi.org/10.2174/15680266113139990094

Ejemplares similares

Tyrosine kinases in rheumatoid arthritis
por: Okamoto, Hiroshi, et al.
Publicado: (2011)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases
por: Szilveszter, Kata P., et al.
Publicado: (2019)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Transport Mechanisms and Their Pathology-Induced Regulation Govern Tyrosine Kinase Inhibitor Delivery in Rheumatoid Arthritis
por: Schmidt-Lauber, Christian, et al.
Publicado: (2012)

The Syk Tyrosine Kinase Is Required for Skin Inflammation in an In Vivo Mouse Model of Epidermolysis Bullosa Acquisita
por: Németh, Tamás, et al.
Publicado: (2017)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Spleen tyrosine kinase Syk is critical for sustained leukocyte adhesion during inflammation in vivo
por: Frommhold, David, et al.
Publicado: (2007)

Protective Role of the MER Tyrosine Kinase via Efferocytosis in Rheumatoid Arthritis Models
por: Waterborg, Claire E. J., et al.
Publicado: (2018)

Importance of Fc Receptor γ-Chain ITAM Tyrosines in Neutrophil Activation and in vivo Autoimmune Arthritis
por: Németh, Tamás, et al.
Publicado: (2019)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis
por: Coffey, Greg, et al.
Publicado: (2013)

Tyrosine kinase inhibitors in sarcoma treatment
por: Kyriazoglou, Anastasios, et al.
Publicado: (2022)

Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis
por: Remuzgo-Martínez, Sara, et al.
Publicado: (2017)

Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care
por: Gillooly, Kathleen M., et al.
Publicado: (2017)

Capsaicin-Sensitive Peptidergic Sensory Nerves Are Anti-Inflammatory Gatekeepers in the Hyperacute Phase of a Mouse Rheumatoid Arthritis Model
por: Botz, Bálint, et al.
Publicado: (2021)

Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis
por: Jin, Pei, et al.
Publicado: (2008)

Tyrosine Kinase Inhibitors and Interferon
por: Dimou, Maria, et al.
Publicado: (2014)

Tyrosine Kinase Inhibitors and Pregnancy
por: Abruzzese, Elisabetta, et al.
Publicado: (2014)

FMS-related tyrosine kinase 3 ligand (Flt3L)/CD135 axis in rheumatoid arthritis
por: Ramos, Maria I, et al.
Publicado: (2013)

Bruton’s tyrosine kinase inhibitors in the treatment of multiple sclerosis
por: Shulga, Olga, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors for the Elderly
por: Hohenforst-Schmidt, Wolfgang, et al.
Publicado: (2016)

Nanomedicine of tyrosine kinase inhibitors
por: Smidova, Veronika, et al.
Publicado: (2021)

Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts
por: Harrach, Saliha, et al.
Publicado: (2017)

Tyrosine kinase inhibitors in osteosarcoma: Adapting treatment strategiesa
por: Assi, Ahmad, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
por: van Leeuwen, Roelof W. F., et al.
Publicado: (2017)

Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition
por: Dowty, Martin E., et al.
Publicado: (2019)

HM71224, a novel Bruton’s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
por: Park, Jin Kyun, et al.
Publicado: (2016)

Latest progress in tyrosine kinase inhibitors
por: Pospelova, Tatiana V., et al.
Publicado: (2014)

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis
por: Hennigan, Stephanie, et al.
Publicado: (2008)

Signal transduction inhibitors for the treatment of rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2012)

Activation of Fms-Like Tyrosine Kinase 3 Signaling Enhances Survivin Expression in a Mouse Model of Rheumatoid Arthritis
por: Andersson, Sofia E. M., et al.
Publicado: (2012)

Tyrosine kinase inhibitors as an alternative treatment in canine mast cell tumor
por: Coelho, Yasmin Nascimento Bernardes, et al.
Publicado: (2023)

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
por: Qu, Kai, et al.
Publicado: (2016)

Bcr-Abl Tyrosine Kinase Inhibitors in the Treatment of Pediatric CML
por: Carofiglio, Francesca, et al.
Publicado: (2020)

Thoracoscopic lobectomy following neoadjuvant tyrosine kinase inhibitor treatment
por: Chudgar, Neel P., et al.
Publicado: (2021)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Drug Retention Rates and the Safety of Janus Kinase Inhibitors in Elderly Patients with Rheumatoid Arthritis
por: Temmoku, Jumpei, et al.
Publicado: (2023)

Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors
por: Koh, Jung Hee, et al.
Publicado: (2023)

Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study
por: Bokarewa, Maria, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_5ebh2fjufjerionhaj2jhfqb3o